On 22 Januray 2016, the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) co-organised a trans-Atlantic workshop discussing clinical trial networks in the field of antimicrobial resistance together with the Innovative Medicines Initiative (IMI), the US National Institute of Health (NIH), the European Commission and COMBACTE. This meeting was the first of its kind.

“The meeting generated very fruitful conversations with represenatives of industry, regulatory agents and principal investigators running clinical trials,” said Laura Marin, coordinator of JPIAMR.

The workhop was preceeded on 20-21 January by the meeting ‘New Frontiers in Antibacterial Resistance Research’ which brought together scientists in the field of antibacterial resistance. The aim was to increase the trans-Atlantic dialogue and encourage scientific collaboration to enhance research addressing antibacterial resistance.

“The first step was to share experiences and increase collaboration. That was the purpose of these two days [20-21 January],” said Dennis Dixon, NIH/NIAID.

The Clinical Trial Workshop Objectives:

  • to share information on current existing initiatives for clinical trial networks for antimicrobial resistance, in order to learn from each other and avoid duplication of efforts;
  •  to discuss challenges and opportunities to overcome barriers for the efficient conduct of high-quality global clinical trials;
  • to foster opportunities for collaboration between the different networks and initiatives in the EU, US, and CA to facilitate clinical research in our fight against AMR;
  • to work towards solutions and recommendations to overcome the barriers identified through better alignment of existing networks and resources.